Jazz Pharmaceuticals Q3 2026 Earnings: Revenue Rises 10% as Actio Charge Drives Loss

Jazz Pharmaceuticals (Nasdaq: JAZZ) reported Q3 2026 revenue of $1.243 billion, up 10% from $1.126 billion a year earlier, while GAAP diluted EPS swung to a loss of $7.48 from earnings of $4.08. A $754.2 million acquired in-process research and development charge tied to the Actio acquisition outweighed revenue growth and lower SG&A expense, producing losses under both GAAP and adjusted measures. Jazz also raised its full-year revenue guidance following growth in Xywav and its oncology portfolio.

Core Financial Results

Revenue growth was primarily driven by higher sales of Xywav, Zepzelca and Ziihera, along with the inclusion of Modeyso following its August 2025 approval. Net product sales increased to $1.197 billion from $1.064 billion, while royalty and contract revenue declined to $46.5 million from $61.7 million.

The quarter ended September 30, 2026, and the results were released on November 2. The main difference from the prior year was the Actio-related acquired IPR&D expense, which rose to $754.2 million from $42.5 million.

Unlike many items excluded from adjusted results, the acquired IPR&D expense remained in Jazz’s non-GAAP calculation. It reduced GAAP EPS by $11.32 and adjusted EPS by $11.03 during the quarter.

Business and Segment Performance

The portfolio showed clear differences between businesses. Sleep revenue increased with continued Xywav patient additions, oncology generated the fastest segment growth, and epilepsy revenue declined modestly because of lower Epidiolex/Epidyolex sales.

Xywav added approximately 425 net patients during the quarter and exited September with about 17,550 active patients, including roughly 11,375 narcolepsy patients and 6,175 idiopathic hypersomnia patients.

Epidiolex/Epidyolex sales decreased 2% to $295.4 million. Jazz attributed the comparison to lower U.S. gross-to-net deductions in the prior-year quarter and less inventory building in Q3 2026 because of wholesaler purchasing patterns.

Oncology growth came from several products. Zepzelca benefited from uptake with atezolizumab in first-line maintenance treatment for extensive-stage small-cell lung cancer, although second-line use declined. The FDA removed Zepzelca’s second-line indication from the label on September 30.

Ziihera received FDA approval on August 25 for first-line treatment of HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma. In its first full month after that launch, average demand vials per selling day increased approximately 40%, and new ordering accounts tripled, with 80% of those accounts in the community setting.

Actio Charge Turned Revenue Growth Into a Quarterly Loss

Jazz completed its acquisition of Actio Biosciences in September, adding ABS-1230, now designated JZP6979, to its rare epilepsy pipeline. The company recorded $754.2 million of acquired IPR&D expense for the value allocated to this program.

That expense explains why higher revenue, a wider GAAP gross margin and lower SG&A spending did not produce quarterly earnings. It also explains the adjusted loss because Jazz did not remove acquired IPR&D from its non-GAAP results.

SG&A expense decreased to $407.9 million from $530.6 million. The prior-year quarter included $152 million of litigation settlements, while Q3 2026 included $34 million of restructuring expense. R&D spending increased to $211.9 million from $198.2 million as Jazz continued investing in its pipeline and evidence generation.

Tax items also made the year-over-year earnings comparison less favorable. Jazz recorded $24.5 million of tax expense in Q3 2026, compared with a $242.4 million tax benefit in Q3 2025 that included a $206 million benefit from recognizing deferred tax assets acquired with Chimerix.

Profitability, Cash Flow and Balance Sheet

GAAP gross margin increased to 91.1% because the inventory fair-value step-up associated with acquisition accounting had been fully recognized in the preceding quarter. Adjusted gross margin moved in the opposite direction, declining to 91.5% from 92.6%, mainly because higher Modeyso and Zepzelca revenue generated additional royalty expense.

Jazz generated $1.33 billion of operating cash flow during the first nine months of 2026, up from $993.3 million in the comparable nine-month period. This is a year-to-date figure and should not be treated as quarterly cash flow.

At September 30, cash, cash equivalents and investments totaled approximately $2.9 billion, while long-term debt principal was $5.6 billion. Jazz also had $885 million of unused revolving credit capacity.

During the quarter, the company issued $1.25 billion of 1.875% exchangeable senior notes due in 2032 and repurchased $225 million of ordinary shares using existing cash. That exhausted its previous repurchase authorization. In October, the board approved a new program authorizing up to $500 million of additional repurchases, without an expiration date. Jazz also reduced the margin on its Term Loan B by 50 basis points and extended its maturity to May 2033.

2026 Financial Guidance

Jazz raised both ends of its full-year revenue range, increasing the lower bound by $175 million and the upper bound by $100 million. It also raised adjusted gross-margin guidance, while higher tax-rate expectations reflected the accounting impact of the Actio acquired IPR&D expense.

Adjusted SG&A and R&D guidance remained at $1.330 billion-$1.370 billion and $725 million-$775 million, respectively. Expected diluted weighted-average shares also remained unchanged at 69 million-70 million.

Recent Insider Transactions

Over the latest six-month period in the supplied insider data, purchase and sale transaction counts were both 16, but shares sold exceeded shares purchased. The result was a net reduction of 43,826 shares, equal to 2.30% of reported insider holdings.

Among the ten latest reported records, six were sales, one was a derivative-security exercise conversion and three were stock grants. These transactions are reported objectively and do not by themselves establish insiders’ views of Jazz’s prospects.

Risks Investors Should Monitor

• Acquisition and pipeline execution: The Actio acquisition caused a substantial current-period expense, while the value of JZP6979 depends on future clinical and regulatory progress. Jazz expected initial patient data from the KYRON trial in Q4 2026.
• Epidiolex sales variability: Revenue declined as gross-to-net comparisons and wholesaler inventory patterns affected results. The FDA action date for the oral cannabidiol capsule application is April 16, 2027.
• Zepzelca’s changing sales mix: Growth is increasingly tied to first-line maintenance use, while second-line demand declined and the FDA removed that indication from the label.
• Launch execution: Raised guidance follows the launches and adoption of products including Ziihera and Modeyso. Future growth depends on sustaining demand and expanding ordering accounts and patient use.
• Debt and capital allocation: Jazz reported $5.6 billion of debt principal against approximately $2.9 billion of cash and investments while continuing acquisitions and share repurchases, making cash generation and financing costs important measures to follow.

Summary

Jazz Pharmaceuticals’ Q3 2026 commercial performance improved, led by Xywav and a growing oncology portfolio, and management raised full-year revenue guidance. However, the Actio-related acquired IPR&D charge turned that operating progress into significant GAAP and adjusted losses. The next areas to monitor are the sustainability of new-product adoption, Epidiolex trends, Zepzelca’s transition toward first-line maintenance use, pipeline execution and the balance between operating cash flow, debt and capital deployment.